Substituted oxoazaheterocyclyl compounds

US7612075B2 · kind B2 · utility

Assignee

• Aventis Pharmaceuticals Inc. · US

Inventors

• William R. Ewing · Yardley, US
• Michael R. Becker · Norristown, US
• Yong Mi Choi-Sledeski · Montgomery, US
• Heinz W. Pauls · Oakville, CA
• Wei He · Audubon, US
• Stephen M. Condon · Glenmoore, US
• Roderick S. Davis · West Chester, US
• Barbara Hanney · Pennsburg, US
• Alfred P. Spada · Lansdale, US
• Christopher J. Burns · Vivonne Bay, AU
• John Ziqi Jiang · Fryeburg, US
• Michael R. Myers · Fishers, US
• Wan Lau · Lawrenceville, US
• Aiwen Li · Westlake Village, US
• Gregory Bernard Poli · Perkasie, US
• Mark Bobko · Exton, US
• Robert L. Morris · Wayne, US
• Joseph M. Karpinski · Douglassville, US
• Timothy Francis Gallagher · Collegeville, US
• Kent W. Neuenschwander · Schwenksville, US
• Robert D. Groneberg · Boulder, US
• Jean-Francois Sabuco · Paris, FR

Key dates

• Filing date: Jul 25, 2003
• Grant date: Nov 3, 2009
• Expiry date: Sep 29, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.